Home ›
Non-Small Cell (NSCLC) Lung Cancer Trials ›
NCT07362940
A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib
This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.
Trial Details
NCT ID NCT07362940 Phase PHASE1 / PHASE2
Sponsor Henan Genuine Biotech Co., Ltd.
Status RECRUITING
Cancer Type Non-Small Cell (NSCLC) Lung Cancer
Interventions GEN-725 tablets + Dositinib mesylate tablets Locations (sample) Beijing, China|39.9075,116.39723 Changsha, China|28.19874,112.97087 Jinan, China|36.66833,116.99722 Xiamen, China|24.47979,118.08187 Zhengzhou, China|34.75778,113.64861
Key Eligibility Criteria
18-75 years old (including 18 and 75 years old), male or female. Patients with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) who are not amenable to c… Patients with a positive EGFR mutation. (For patients with prior third-generation EGFR-TKI therapy, post-progression EGFR mutation test results are… a) Phase Ⅰ Dose Escalation Stage: EGFR-mutant NSCLC patients who have received at least one prior line of therapy (chemotherapy or targeted therapy… For full eligibility, visit ClinicalTrials.gov .